journal
MENU ▼
Read by QxMD icon Read
search

Drugs

journal
https://www.readbyqxmd.com/read/30635838/fexinidazole-first-global-approval
#1
Emma D Deeks
Fexinidazole Winthrop (hereafter referred to as fexinidazole) is a DNA synthesis inhibitor developed by the Drugs for Neglected Diseases initiative (DNDi), in collaboration with Sanofi, for the oral treatment of human African trypanosomiasis (HAT) [commonly known as 'sleeping sickness'] and Chagas' disease. The drug is a 5-nitroimidazole derivative first discovered by Hoechst AG (now part of Sanofi) and was identified by the DNDi in 2005 as having activity against Trypanosoma brucei gambiense and T. b. rhodesiense...
January 11, 2019: Drugs
https://www.readbyqxmd.com/read/30635837/larotrectinib-first-global-approval
#2
Lesley J Scott
Larotrectinib (VITRAKVI® ) is an orally administered, small molecule, highly-selective, tropomyosin receptor kinase (TRK) inhibitor that was developed by Loxo Oncology in collaboration with Bayer AG as a treatment for adult and paediatric patients whose cancers harbour neurotrophic receptor tyrosine kinase (NTRK) gene fusions. In November 2018 larotrectinib received its first global approval in the USA for the treatment of adult and paediatric patients with solid tumours that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment...
January 11, 2019: Drugs
https://www.readbyqxmd.com/read/30623349/achieving-glycaemic-control-with-concentrated-insulin-in-patients-with-type-2-diabetes
#3
REVIEW
Sudesna Chatterjee, Kamlesh Khunti, Melanie J Davies
The recent introduction of the second-generation long-acting analogue insulins degludec and insulin glargine U300 have increased the choice of basal insulin therapy for patients with type 2 diabetes. The pharmacokinetic and pharmacodynamic properties of these insulins result in a flatter profile that lasts over 24 h and provides an increased window of administration of 6 h once daily. Large-scale multicentre randomised clinical trial programmes (BEGIN for degludec U100 and U200 and EDITION for glargine U300) evaluating these insulin therapies against glargine U100 have demonstrated that they are either non-inferior or superior for glycaemic efficacy and safety, but less likely to result in severe or nocturnal hypoglycaemia than glargine U100...
January 8, 2019: Drugs
https://www.readbyqxmd.com/read/30623348/pharmacotherapy-for-neuromyelitis-optica-spectrum-disorders-current-management-and-future-options
#4
REVIEW
Nicolas Collongues, Estelle Ayme-Dietrich, Laurent Monassier, Jérôme de Seze
Neuromyelitis optica (NMO) is an inflammatory and demyelinating disease of the central nervous system. Although the prevalence of NMO is low, the rapid and severe impairment observed in patients has led to extensive development of research in the fields of diagnostic criteria and therapy in the past 15 years. With improved understanding of the pathophysiology of NMO and the role of aquaporin-4 (AQP4) or myelin oligodendrocyte glycoprotein antibodies, numerous therapeutic approaches have been proposed and are currently undergoing evaluation...
January 8, 2019: Drugs
https://www.readbyqxmd.com/read/30623347/botulinum-toxin-type-a-for-the-treatment-of-lower-limb-spasticity-after-stroke
#5
REVIEW
Andrea Santamato, Nicoletta Cinone, Francesco Panza, Sara Letizia, Luigi Santoro, Madia Lozupone, Antonio Daniele, Alessandro Picelli, Alessio Baricich, Domenico Intiso, Maurizio Ranieri
Post-stroke lower limb spasticity impairs balance and gait leading to reduced walking speed, often increasing wheelchair use and caregiver burden. Several studies have shown that appropriate treatments for lower limb spasticity after stroke include injections of botulinum toxin type A (BoNT-A), phenol or alcohol, surgical correction and a rehabilitation program. In the present article, we review the safety and effectiveness of BoNT-A for the treatment of lower limb spasticity after stroke, with a focus on higher doses of BoNT-A...
January 8, 2019: Drugs
https://www.readbyqxmd.com/read/30623346/emapalumab-first-global-approval
#6
Zaina T Al-Salama
Emapalumab-Izsg (hereafter referred to as emapalumab) [Gamifant® ] is a monoclonal antibody directed against interferon gamma that is available as an intravenous infusion. Emapalumab is being developed by Novimmune and Swedish Orphan Biovitrum for the treatment of haemophagocytic lymphohistiocytosis (HLH). In November 2018, emapalumab received its first global approval in the USA, for the treatment of paediatric (newborn and older) and adult patients with primary HLH, who have refractory, recurrent or progressive disease or intolerance to conventional HLH therapy...
January 8, 2019: Drugs
https://www.readbyqxmd.com/read/30617959/the-role-of-fluoroquinolones-in-the-treatment-of-tuberculosis-in-2019
#7
REVIEW
A D Pranger, T S van der Werf, J G W Kosterink, J W C Alffenaar
The inability to use powerful antituberculosis drugs in an increasing number of patients seems to be the biggest threat towards global tuberculosis (TB) elimination. Simplified, shorter and preferably less toxic drug regimens are being investigated for pulmonary TB to counteract emergence of drug resistance. Intensified regimens with high-dose anti-TB drugs during the first weeks of treatment are being investigated for TB meningitis to increase the survival rate among these patients. Moxifloxacin, gatifloxacin and levofloxacin are seen as core agents in case of resistance or intolerance against first-line anti-TB drugs...
January 7, 2019: Drugs
https://www.readbyqxmd.com/read/30617958/targeting-angiogenesis-in-colorectal-carcinoma
#8
REVIEW
Anthony Lopez, Kazuto Harada, Maria Vasilakopoulou, Namita Shanbhag, Jaffer A Ajani
Neo-angiogenesis plays a key role in colorectal cancer, with the vascular endothelial growth factor family proteins and their receptors in particular triggering multiple signaling networks that result in endothelial cell survival, migration, mitogenesis, differentiation, and vascular permeability. Anti-angiogenic therapies have improved colorectal cancer prognosis within the past 15 years. Bevacizumab demonstrated efficacy in combination with chemotherapy under different conditions, including as first- and second-line therapies, and also as a maintenance treatment strategy...
January 7, 2019: Drugs
https://www.readbyqxmd.com/read/30612319/disease-modifying-therapies-in-type-1-diabetes-a-look-into-the-future-of-diabetes-practice
#9
REVIEW
Carla Greenbaum, Dana VanBuecken, Sandra Lord
The novel understanding that the presence of multiple islet autoantibodies, indicating islet autoimmunity, inevitably leads to type 1 diabetes mellitus (T1DM) has necessitated the development of a new staging classification system for the condition. Coupled with an improved understanding of the disease course, the realization that T1DM appears to be more heterogeneous than previously thought has led to unique opportunities to develop more targeted therapies that may be applied even before the onset of dysglycemia or symptoms...
January 5, 2019: Drugs
https://www.readbyqxmd.com/read/30612318/correction-to-moxetumomab-pasudotox-first-global-approval
#10
Sohita Dhillon
The article Moxetumomab Pasudotox: First Global Approval, written by Sohita Dhillon, was originally published Online First without open access.
January 5, 2019: Drugs
https://www.readbyqxmd.com/read/30610623/correction-to-ivosidenib-first-global-approval
#11
Sohita Dhillon
IThe article Ivosidenib: First Global Approval, written by Sohita Dhillon, was originally published Online First without open access.
January 4, 2019: Drugs
https://www.readbyqxmd.com/read/30604292/immune-checkpoint-inhibitors-in-the-treatment-of-gastroesophageal-cancer
#12
Maxime Chénard-Poirier, Elizabeth C Smyth
Immune checkpoint blockade has revolutionised the treatment of multiple cancers including melanoma, non-small cell lung cancer, urothelial and renal cell cancers. For patients with chemorefractory gastroesophageal cancer, treatment with anti-PD-1 therapy results in modest benefits in overall survival; nivolumab and pembrolizumab have been licenced in Japan and the USA, respectively, for this indication. However, initial enthusiasm has been tempered by the results of several large negative trials; immune checkpoint blockade is not superior to chemotherapy in the second-line setting or beyond in unselected or low PD-L1-expressing patients...
January 2, 2019: Drugs
https://www.readbyqxmd.com/read/30604291/lorlatinib-first-global-approval
#13
Yahiya Y Syed
Lorlatinib is an oral small molecule inhibitor of anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (ROS1) kinase developed by Pfizer for the treatment of ALK-positive non-small cell lung cancer (NSCLC). Based on results from a phase I/II trial, lorlatinib received approval in Japan in September 2018 and in the USA in November 2018 for the treatment of ALK-positive NSCLC. This article summarizes the milestones in the development of lorlatinib leading to the first global approval for this indication.
January 2, 2019: Drugs
https://www.readbyqxmd.com/read/30588564/current-and-emerging-therapies-for-non-alcoholic-fatty-liver-disease
#14
REVIEW
Samarth Siddharth Patel, Mohammad Shadab Siddiqui
Non-alcoholic fatty liver disease is the most common cause of chronic liver disease in the developed world and commonly associated with metabolic comorbidities such as diabetes mellitus, hypertension, dyslipidemia, and obesity. Non-alcoholic steatohepatitis is an aggressive form of non-alcoholic fatty liver disease, associated with an increased risk of liver and non-liver-related mortality. Currently there are no approved therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and standard-of-care lifestyle advice is rarely effective...
December 26, 2018: Drugs
https://www.readbyqxmd.com/read/30588563/recent-developments-in-male-contraception
#15
Arthi Thirumalai, Stephanie T Page
Unplanned pregnancies are an ongoing global burden, posing health and economic risks for women, children, and families. Advances in male contraception have been historically stymied by concerning failure rates, problematic side effects, and perceived market limitations. However, increased interest in reliable and reversible options for male contraception have resulted in resurgent efforts to introduce novel contraceptives for men. Hormonal male contraception relies on exogenous androgens and progestogens that suppress gonadotropin production, thereby suppressing testicular testosterone and sperm production...
December 26, 2018: Drugs
https://www.readbyqxmd.com/read/30560479/targeted-systemic-treatment-of-neuroendocrine-tumors-current-options-and-future-perspectives
#16
REVIEW
Aura D Herrera-Martínez, Johannes Hofland, Leo J Hofland, Tessa Brabander, Ferry A L M Eskens, María A Gálvez Moreno, Raúl M Luque, Justo P Castaño, Wouter W de Herder, Richard A Feelders
Neuroendocrine tumors (NETs) originate from the neuroendocrine cell system in the bronchial and gastrointestinal tract and can produce hormones leading to distinct clinical syndromes. Systemic treatment of patients with unresectable NETs aims to control symptoms related to hormonal overproduction and tumor growth. In the last decades prognosis has improved as a result of increased detection of early stage disease and the introduction of somatostatin analogs (SSAs) as well as several new therapeutic options...
December 17, 2018: Drugs
https://www.readbyqxmd.com/read/30560478/revefenacin-first-global-approval
#17
Young-A Heo
Revefenacin (YUPELRI™) inhalation solution, a long-acting muscarinic antagonist (i.e. an anticholinergic) developed by Theravance Biopharma and Mylan, is the first and currently the only once-daily, nebulized bronchodilator to be approved in the USA for the treatment of chronic obstructive pulmonary disease (COPD). In November 2018, based on results of three phase III trials, the US Food and Drug Administration granted market authorization to revefenacin for the maintenance treatment of patients with COPD...
December 17, 2018: Drugs
https://www.readbyqxmd.com/read/30539513/correction-to-daunorubicin-cytarabine-liposome-a-review-in-acute-myeloid-leukaemia
#18
Hannah A Blair
The original article has been corrected.
December 12, 2018: Drugs
https://www.readbyqxmd.com/read/30511323/daunorubicin-cytarabine-liposome-a-review-in-acute-myeloid-leukaemia
#19
Hannah A Blair
VYXEOS™ is a liposomal-encapsulated formulation of daunorubicin and cytarabine delivering a fixed, synergistic 1:5 molar ratio (hereafter referred to as daunorubicin/cytarabine liposome). Daunorubicin/cytarabine liposome is approved in several countries worldwide for the treatment of adults with therapy-related acute myeloid leukaemia (tAML) and AML with myelodysplasia-related changes (MRC). Approval was based on its clinical benefit in older patients with newly diagnosed high-risk/secondary AML in a pivotal phase III trial...
December 3, 2018: Drugs
https://www.readbyqxmd.com/read/30511322/correction-to-caplacizumab-first-global-approval
#20
Sean Duggan
The article Caplacizumab: First Global Approval, written by Sean Duggan, was originally published Online First without open access.
December 3, 2018: Drugs
journal
journal
26573
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"